DK2111555T3 - Diagnosticering af præeklampsi - Google Patents

Diagnosticering af præeklampsi

Info

Publication number
DK2111555T3
DK2111555T3 DK08707674.1T DK08707674T DK2111555T3 DK 2111555 T3 DK2111555 T3 DK 2111555T3 DK 08707674 T DK08707674 T DK 08707674T DK 2111555 T3 DK2111555 T3 DK 2111555T3
Authority
DK
Denmark
Prior art keywords
clampsy
diagnostication
Prior art date
Application number
DK08707674.1T
Other languages
English (en)
Inventor
Stefan Hansson
Bo Aakerstroem
Original Assignee
A1M Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A1M Pharma Ab filed Critical A1M Pharma Ab
Application granted granted Critical
Publication of DK2111555T3 publication Critical patent/DK2111555T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99003—Heme oxygenase (1.14.99.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
DK08707674.1T 2007-02-12 2008-02-12 Diagnosticering af præeklampsi DK2111555T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0700339 2007-02-12
PCT/EP2008/001051 WO2008098734A1 (en) 2007-02-12 2008-02-12 Diagnosis and treatment of preeclampsia

Publications (1)

Publication Number Publication Date
DK2111555T3 true DK2111555T3 (da) 2013-09-02

Family

ID=39295873

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08707674.1T DK2111555T3 (da) 2007-02-12 2008-02-12 Diagnosticering af præeklampsi
DK13160275.7T DK2614832T3 (da) 2007-02-12 2008-02-12 Diagnose og behandling af præeklampsi

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13160275.7T DK2614832T3 (da) 2007-02-12 2008-02-12 Diagnose og behandling af præeklampsi

Country Status (18)

Country Link
US (3) US8568999B2 (da)
EP (3) EP2111555B1 (da)
JP (2) JP5604111B2 (da)
KR (2) KR101454013B1 (da)
AU (1) AU2008214837B2 (da)
BR (1) BRPI0808340A2 (da)
CA (1) CA2674204C (da)
DK (2) DK2111555T3 (da)
EA (2) EA031877B1 (da)
ES (2) ES2426069T3 (da)
HR (2) HRP20130809T1 (da)
HU (1) HUE031613T2 (da)
MX (2) MX347788B (da)
NZ (1) NZ578077A (da)
PL (2) PL2111555T3 (da)
PT (2) PT2614832T (da)
WO (1) WO2008098734A1 (da)
ZA (1) ZA200905101B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2111555T3 (da) 2007-02-12 2013-09-02 A1M Pharma Ab Diagnosticering af præeklampsi
EP2638915B1 (en) * 2008-07-18 2016-10-19 A1M Pharma AB Medical use of the radical scavenger and antioxidant alpha-1-microglobulin
WO2011095981A1 (en) * 2010-02-03 2011-08-11 St. John's Research Institute An in-vitro method for characterizing hemoglobin variant
ES2543171T3 (es) * 2010-03-24 2015-08-17 Preelumina Diagnostics Ab HbF y A1M como marcadores de fase inicial para preeclampsia
US9903865B2 (en) * 2010-03-31 2018-02-27 Sekisui Medical Co., Ltd. Assay, immunochromatographic test strip, and assay reagent kit for measuring an analyte, using a hematocrit correction
WO2013053359A1 (en) 2011-10-14 2013-04-18 Aarhus Universitet Diagnostic and prognostic use of prombp-complexes
AU2013311714C1 (en) * 2012-09-05 2018-01-25 A1M Pharma Ab Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
US10928402B2 (en) 2012-12-28 2021-02-23 Nx Prenatal Inc. Treatment of spontaneous preterm birth
US20140186332A1 (en) * 2012-12-28 2014-07-03 NX Pharmagen Biomarkers of preterm birth
WO2016146647A1 (en) 2015-03-16 2016-09-22 A1M Pharma Ab Biomarkers for preeclampsia
KR101732933B1 (ko) 2015-07-29 2017-05-08 영남대학교 산학협력단 신생아의 성장 또는 심혈관계 질환 예후 진단 방법
CN109072479A (zh) 2015-12-04 2018-12-21 Nx产前公司 使用循环微粒对自发性早产风险进行分层
BR112020015291B1 (pt) 2018-03-19 2023-09-26 Regeneron Pharmaceuticals, Inc Tampão de amostra de eletroforese aquoso, método para identificar contaminantes ou impurezas em uma amostra de fármaco proteico, e, kit
US11418353B2 (en) * 2019-08-26 2022-08-16 Micron Technology, Inc. Security descriptor generation
CN111626280B (zh) * 2020-04-13 2021-09-07 北京邮电大学 一种无定位点答题卡识别方法和装置
WO2024053586A1 (ja) * 2022-09-05 2024-03-14 栄研化学株式会社 遊離ヘモグロビン測定試薬、遊離ヘモグロビン測定方法および抗ヘモグロビン抗体

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1337778A1 (ru) 1984-06-25 1987-09-15 Новосибирский государственный медицинский институт Способ диагностики т жести позднего токсикоза беременных
US5079171A (en) 1988-09-15 1992-01-07 Adeza Biomedical Corporation Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin
US5238819A (en) 1988-12-14 1993-08-24 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5108898A (en) 1989-01-18 1992-04-28 Peters John H Use of fibronectin having a variable included type III repeat sequence as a marker for toxemia in pregnancy
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
US6103691A (en) 1994-03-23 2000-08-15 Tschesche; Harald Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins
US5849474A (en) * 1995-12-06 1998-12-15 Olson; Camilla M. Diagnosis of preeclampsia in mammals
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6169816B1 (en) * 1997-05-14 2001-01-02 Applied Imaging, Inc. Identification of objects of interest using multiple illumination schemes and finding overlap of features in corresponding multiple images
JP2001348342A (ja) 2001-04-12 2001-12-18 Nippon Zoki Pharmaceut Co Ltd 免疫調整・抗炎症剤
DE60233301D1 (de) 2001-05-04 2009-09-24 Biosite Inc Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
ES2284911T3 (es) 2001-09-04 2007-11-16 Iq Corporation B.V. Determinacion y cuantificacion de poblaciones de globulos rojos en muestras.
EP1491891A4 (en) * 2002-03-29 2005-11-09 Matsushita Electric Ind Co Ltd METHOD AND DEVICE FOR TREATING BLOOD, METHOD AND DEVICE FOR MEASURING HEMOGLOBINS
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
JP5624256B2 (ja) * 2003-06-20 2014-11-12 ラプター・ファーマシューティカル・インコーポレイテッド 脳および他の組織への治療化合物の送達
AR045074A1 (es) 2003-07-23 2005-10-12 Applied Research Systems Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
EP1689386A1 (en) * 2003-11-26 2006-08-16 Sanofi-Aventis Deutschland GmbH Tubular proteinuria as an indicator for elevated cardiovascular risk
WO2005093413A2 (en) * 2004-03-22 2005-10-06 Yale University Diagnosis and treatment of preeclampsia
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
GB0600916D0 (en) 2006-01-17 2006-02-22 Perkinelmer Instr Las Inc detecting and predicting pre-eclampsia
CA2636353A1 (en) 2006-01-18 2007-07-26 Georg Wick Test systems for the analysis of polypeptides and cells adhering to silicones
DK2111555T3 (da) 2007-02-12 2013-09-02 A1M Pharma Ab Diagnosticering af præeklampsi
WO2009108073A1 (en) 2008-02-28 2009-09-03 Auckland Uniservices Limited Biomarkers for prediction of preeclampsia and/or cardiovascular disease
EP2638915B1 (en) 2008-07-18 2016-10-19 A1M Pharma AB Medical use of the radical scavenger and antioxidant alpha-1-microglobulin
ES2543171T3 (es) 2010-03-24 2015-08-17 Preelumina Diagnostics Ab HbF y A1M como marcadores de fase inicial para preeclampsia

Also Published As

Publication number Publication date
ES2599003T3 (es) 2017-01-31
JP2014012670A (ja) 2014-01-23
EP2614832A1 (en) 2013-07-17
EP2111555B1 (en) 2013-05-29
PL2614832T3 (pl) 2017-01-31
MX2009008408A (es) 2009-11-02
US20180284087A1 (en) 2018-10-04
EA200970758A1 (ru) 2010-02-26
NZ578077A (en) 2012-04-27
KR101454013B1 (ko) 2014-11-12
WO2008098734A1 (en) 2008-08-21
EP2613150A1 (en) 2013-07-10
CA2674204C (en) 2017-07-11
US20100105070A1 (en) 2010-04-29
AU2008214837B2 (en) 2013-01-10
KR20140095572A (ko) 2014-08-01
PT2614832T (pt) 2016-10-18
AU2008214837A1 (en) 2008-08-21
US20140065170A1 (en) 2014-03-06
BRPI0808340A2 (pt) 2017-05-30
US8568999B2 (en) 2013-10-29
EA201500335A1 (ru) 2016-08-31
PL2111555T3 (pl) 2013-10-31
HRP20130809T1 (en) 2013-10-11
CA2674204A1 (en) 2008-08-21
JP5792772B2 (ja) 2015-10-14
PT2111555E (pt) 2013-09-04
ES2426069T3 (es) 2013-10-21
EA022609B1 (ru) 2016-02-29
EA031877B1 (ru) 2019-03-29
JP2010518386A (ja) 2010-05-27
JP5604111B2 (ja) 2014-10-08
EP2614832B1 (en) 2016-07-13
HRP20161266T1 (hr) 2016-12-16
MX347788B (es) 2017-05-12
DK2614832T3 (da) 2016-10-31
KR101608501B1 (ko) 2016-04-04
US10359406B2 (en) 2019-07-23
ZA200905101B (en) 2012-01-25
HUE031613T2 (en) 2017-09-28
EP2111555A1 (en) 2009-10-28
KR20100015315A (ko) 2010-02-12

Similar Documents

Publication Publication Date Title
DK2111555T3 (da) Diagnosticering af præeklampsi
DK2262793T3 (da) Krystallinske former af nilotinib-hci
DK2099973T3 (da) Udfoldning af gabion
DK2264042T3 (da) Mikronisering af polyoler
DK2084174T3 (da) Fremstilling af ribofuranosylpyrimidinnukleotider
DK2041270T3 (da) Fremstilling af glycoproteiner
ATE542825T1 (de) Substituierte piperidino-dihydrothienopyrimidine
DK2205737T3 (da) Mikromirer
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
BRPI0821573A2 (pt) benzofuropirimidonas
ATE501136T1 (de) Imidazopyridinone
DK2700786T3 (da) Modifikation af overførselspassage
DK2219469T3 (da) Modificering af enzymatisk disponerede proteiner
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
BRPI0811451A2 (pt) Exopolissacarídeo
DK2153565T3 (da) Valg af transmissionsmodus
DK2114147T3 (da) Reduktion af bivirkninger af tramadol
BRPI0812840A2 (pt) 2-imidazolinas
DK2117732T3 (da) Frembringelse af partier
DK2178900T3 (da) Oprensning af pegylerede polypeptider
AT505058A3 (de) Türschliesssystem
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
BRPI0812994A2 (pt) Microbiocidas
DE112008001216A5 (de) Magnetronplasmaanlage
DK2181065T3 (da) Partialoxidation af carbonhydrider